Gender and Racial Disparity in Peritoneal Dialysis Patients Undergoing Kidney Transplantation

ASAIO Journal ◽  
1997 ◽  
Vol 43 (5) ◽  
pp. M865
Author(s):  
BARBARA G. DELANO ◽  
LEILA MACEY ◽  
ELI A. FRIEDMAN
PLoS ONE ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. e0227870
Author(s):  
Laurisson Albuquerque da Costa ◽  
Maria Cláudia Cruz Andreoli ◽  
Aluizio Barbosa Carvalho ◽  
Sérgio Antonio Draibe ◽  
José Osmar Medina Pestana ◽  
...  

2018 ◽  
Vol 19 (2) ◽  
pp. 172-176 ◽  
Author(s):  
Dinesh Bansal ◽  
Vijay Kher ◽  
Krishan Lal Gupta ◽  
Debasish Banerjee ◽  
Vivekanand Jha

Introduction: Despite the growing number of haemodialysis (HD) patients in India, little is known about vascular access practice. We investigated the use and cost of different vascular accesses by Indian nephrologists. Methods: An online survey was emailed to 920 Indian nephrologists and 388 (42.1%) responded; 98.5% of whom were responsible for managing dialysis patients, 98% in hospitals. Results: Sixty-four percent of patients initiated renal replacement therapy with HD, 7% with peritoneal dialysis, 10% kidney transplantation and 19% conservative care. Forty-eight percent of patients were self-paying, 26% had employee reimbursement and 23% had insurance. According to 59% of responders, more than three-quarters of patients started dialysis with uncuffed catheter, less than one-quarter started dialysis with fistula; and very few used grafts or tunnelled catheters. Among prevalent HD patients, over half were dialysing with fistula (79% nephrologists), rather than uncuffed catheters (15% nephrologists) or grafts (<1% nephrologists). Sixteen percent reported at least one catheter-related sepsis in more than half of patients. Placement of uncuffed catheters cost US$160 in 92% facilities, whereas tunnelled catheters cost US$320 in 46% of facilities. An arteriovenous fistula (AVF) could be created for US$160 in 40%, and US$320 in 90% of centres. Thirty-five percent of nephrologists reported that grafts were not placed at their institute and where they were available, the average cost was over US$480. Forty-six percent of nephrologists had access to pre-dialysis clinics, <30% to vascular access programmes, and <17% conducted regular vascular access audits. Conclusions: The survey provides a snapshot of the current status of vascular access care in HD patients and highlights need for pre-dialysis clinics, vascular access services and registry audits.


2018 ◽  
Vol 50 (1) ◽  
pp. 160-164
Author(s):  
Y. Ayar ◽  
A. Ersoy ◽  
G. Ocakoglu ◽  
E. Gullulu ◽  
H. Kagızmanlı ◽  
...  

1994 ◽  
Vol 14 (3_suppl) ◽  
pp. 162-168 ◽  
Author(s):  
Rosario Maiorca ◽  
Silvio Sandrini ◽  
Giovanni C. Cancarini ◽  
Corrado Camerini ◽  
Francesco Scolari ◽  
...  

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Valerio Vizzardi ◽  
Diana Bertoni ◽  
Vincenzo Terlizzi ◽  
Alessandra Pola ◽  
MAttia Tonoli ◽  
...  

Abstract Background and Aims Encapsulating peritoneal sclerosis (EPS) is a rare but severe complication of peritoneal dialysis (PD). Its prevalence, ranging from 0.7 to 3.3%, and its reported mortality is 25-55%. Post-transplantation encapsulating peritoneal sclerosis (PT-EPS) usually occurs within two years from PD interruption due to kidney transplantation. Calcineurin inhibitors are thought to be involved in the pathogenesis of PT-EPS. Method This is a retrospective, single-center study: all the patients who received PD for 2 or more months before kidney transplantation between 1979 and 2018 in our unit were enrolled. All PD patients diagnosed with EPS after transplantation were identified, and their data were compared with those of non-transplanted PD patients (NT-PD). Results Data from a total of 1014 PD patients were examined; 215 underwent kidney transplantation and 799 remained on PD. PT-EPS occurred in 5/215 patients (2.3%), a prevalence not significantly different from that of NT-PD (21/799= 2.6%; P = 0.39) (Table 1). Calcineurin inhibitors were administered to 178/215 (83%) patients without EPS and all 5 patients with PT-EPS (P = 0.68). Calcineurin inhibitors were associated with corticosteroids (41%), mycophenolate mofetil (34%), or both (42%). Inhibitors of mammalian targets of rapamycin were used in association with calcineurin inhibitors in 25%, with calcineurin inhibitors and steroids in 24% and steroids alone in 7%. Mortality due to PT-EPS was 4.3% vs 1.2% in NT-PD (P = 0.38) (Figure 1). Conclusion The prevalence of PT-EPS was similar to that of EPS in NT-PD. Therapy with calcineurin inhibitors did not appear to be a crucial risk key in the development of PT-EPS.


Sign in / Sign up

Export Citation Format

Share Document